At BOC Sciences, we deliver end-to-end solutions in Glyco-Optimized Antibody Therapeutics, empowering biotech and pharmaceutical innovators to develop biologics that are not only more effective but also safer and more consistent. Through advanced glycan engineering technologies-including host cell line modification, enzymatic glyco-remodeling, and site-specific glycan-based conjugation-we precisely tailor antibody glycosylation patterns to enhance ADCC activity, improve pharmacokinetics, reduce immunogenicity, and enable next-generation antibody-drug conjugates (ADCs). With a proven track record of bridging cutting-edge research and scalable GMP manufacturing, we help our partners accelerate drug discovery and bring best-in-class therapeutic antibodies to market with confidence.
Our glyco-optimization solutions are designed to address critical limitations in traditional antibody therapeutics:
Enhanced Efficacy & Potency: Reduce core fucose to dramatically boost FcγRIIIa binding and maximize Antibody-Dependent Cellular Cytotoxicity (ADCC).
Improved Safety Profile: Eliminate immunogenic non-human glycans, lowering the risk of adverse immune responses.
Consistent Quality: Achieve uniform glycan profiles across production batches, minimizing variability and ensuring reliable therapeutic performance.
Optimized Pharmacokinetics: Extend half-life and circulation time through targeted sialylation or galactosylation strategies.
Next-Gen ADC Platforms: Enable site-specific, stable drug conjugation using engineered glycosylation sites, improving antibody-drug conjugate (ADC) homogeneity and therapeutic index.
We design and customize host cell lines to produce antibodies with optimized glycosylation patterns from the very beginning of development.
We apply enzyme-based in vitro remodeling to achieve highly homogeneous, human-like glycan structures.
We enable site-specific antibody-drug conjugation (ADC) by leveraging glycan sites for precise and stable drug attachment.
We provide state-of-the-art analysis to fully characterize antibody glycosylation and meet regulatory expectations.
We support the entire journey from lab discovery to GMP-compliant large-scale production.
Partnering with us gives you a competitive edge in biologics development.
Scientific Expertise in Glyco-Engineering: A multidisciplinary team with deep knowledge of antibody glycosylation, from Fc optimization to site-specific ADC conjugation.
End-to-End Solutions: One-stop service covering design, development, analytical profiling, process optimization, and GMP manufacturing.
Scalable & Cost-Efficient: Flexible platforms that accelerate timelines while reducing development costs.
Proven Track Record: Successful collaborations with leading biotech and pharmaceutical companies, delivering real-world therapeutic impact.
Our streamlined workflow ensures your antibody development project moves efficiently from concept to clinical readiness.
In-depth evaluation of your scientific goals and therapeutic targets.
Customized project roadmap aligned with regulatory and commercial milestones.
Technical feasibility studies to identify the optimal glyco-engineering strategy.
Tailored cell line engineering or glyco-remodeling plan creation.
Laboratory-scale proof-of-concept with validated analytical readouts.
Early risk assessment to anticipate potential manufacturing challenges.
Process refinement for improved yield, stability, and reproducibility.
Pilot production runs for preclinical and IND-enabling studies.
Robust quality control.
Seamless transition into GMP-grade production.
Regulatory-compliant documentation and analytical support.
On-time delivery with full traceability and batch consistency.
Glyco-optimization refers to the engineering of antibody glycosylation patterns to improve efficacy, safety, pharmacokinetics, and manufacturability.
Glycans on the Fc region influence antibody stability, receptor binding, ADCC/CDC activity, half-life, and immunogenicity. Controlling these glycans allows for predictable therapeutic outcomes.
Oncology, autoimmune disorders, infectious diseases, and neurological conditions are the main focus areas, though applications continue to expand.
Through host cell line engineering, in vitro chemoenzymatic glyco-remodeling, or site-specific conjugation methods.
Glyco-optimized ADCs feature site-specific drug attachment at glycan sites, ensuring consistent drug-to-antibody ratios (DAR), enhanced stability, and reduced off-target toxicity.
Partner with BOC Sciences to unlock the full potential of Glyco-Optimized Antibody Therapeutics. Whether you are advancing oncology antibodies, developing next-generation ADCs, or designing safer biologics, our glyco-engineering expertise delivers the consistency, potency, and scalability your program needs.
We offer access to a broad range of custom glycans, including:
Afucosylated Glycans - for enhanced ADCC activity.
Galactosylated Glycans - improving Fc stability and complement activation.
Sialylated Glycans - extending half-life and enabling anti-inflammatory properties.
Engineered Functionalized Glycans - introducing reactive handles for site-specific conjugation.
Contact us today to discuss your project and discover how our glyco-engineering solutions can bring your therapeutic antibodies to the next level.
